The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis
Authors' conclusion
Treatment with ROMO yields larger increases in BMD than TPTD after 12 months and a higher rate of completion. ROMO was associated with a higher adherence.
Study context
- Population
- Postmenopausal women with osteoporosis meeting reimbursement criteria for romosozumab (ROMO) or TPTD, Department of Endocrinology, Aarhus University Hospital
- Participants
- 315 women
- Exposure
- Romosozumab vs teriparatide
- Outcome
- Percentage change from baseline in BMD (FN, TH and LS) by DXA
- Follow-up
- Month 12
Methodological detailssingle-centre, data from medical records
- Single-centre
- Data from medical records
Main finding
As reported in the abstract
Percentage change in BMD
FN bone mineral density (BMD) increase, ROMO vs TPTD
4.8% vs 0.2%
TH BMD increase, ROMO vs TPTD
5.7% vs 0.3%
LS BMD increase, ROMO vs TPTD
13.7% vs 9.3%
Observational data: associations, not effects.
Further findings
Discontinuation
- Discontinuation rate lower with ROMO than TPTD
BMD increase by prior treatment
- Treatment-naïve patients had nonsignificantly higher BMD increases than previously treated, with both ROMO and TPTD
Safety
Cardiovascular adverse events
- Lower incidence of cardiovascular AEs with ROMO vs TPTD
Original publication
The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis. J Clin Endocrinol Metab. Published 16 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →